'
Zydus
Lifesciences hosted a conference call on Nov 6, 2025. In the conference call,
the company was represented by, Dr. Sharvil Patel, Managing Director.
Key takeaways of the call
In
Q2 FY26, the India business contributed 37% to the total revenue, with
Formulations accounting for 26% and Consumer Wellness for 11%. US Formulations
contributed 45%, International Formulations 13%, APIs 2%, and Medtech and
others 3%.
In
Q2 FY25, the India Formulations business grew 8.4% YoY, Consumer Wellness was
up 30.7% YoY, US Formulations rose 13.5% YoY, and International Formulations
increased 39.4% YoY. Revenue from the API segment increased 23.3% YoY, and the
Alliances & Others segment was down 85.1% YoY.
In
H1 FY26, the India business contributed 37% to the total revenue, with
Formulations accounting for 25% and Consumer Wellness for 12%. US Formulations
contributed 47%, Internation...
Pleaselogin & subscribe to view the full report.
More Reports
-
(05-Feb-2025)
Castrol India
Expects EBITDA margin of 22%-25% for CY25
-
(10-Feb-2023)
Deepak Nitrite
Plans capex of about Rs 1500 crore for FY23 and FY24
-
(09-Feb-2023)
Mayur Uniquoters
Targets revenue of Rs 1000 crore in FY24
-
(31-Jan-2023)
Tega industries
Capex plan is US$ 30-32 million for next three years
|
|